预约演示
Akari Therapeutics enters merger deal with Peak Bio
2024-03-06
孤儿药免疫疗法快速通道临床3期临床2期
The merger brings together Akari’s advanced clinical programmes and new drug candidates of Peak Bio. Credit: PeopleImages.com – Yuri A / Shutterstock.com.
Akari Therapeuticswill operate under the name Akari TherapPeak Biolc.
Shareholders of both companies will hold approAkari Therapeutics Plc.the new entity.
The merger brings together Akari’s advanced clinical programmes and new drug candidates of Peak Bio.
See Also:PTC Therapeutics files patent for pharmaceutical composition for treating various diseases
Sorrento PTC TherapeuticsPTCrapeutics files patent for stable oral liquid pharmaceutical composition of celecoxib for pain relief
The combined business will merge chemotherapy with immunotherapy strategies for the development of new solutions for cancer.
Sorrento Therapeutics nomacopan, is a bispecific recombinant inhibitor of complement C5 celecoxibtrienpain.
This product is currently in a Phase III clinical trial for paediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
The FDA previously granted orphan drug, fast track and rare paediatric disease designations to nomacopan for this patcanceropulation.
Akariso received orphanomacopansignation from the European Commission for complement C5 of hematopoietic stem cell transplantation.
Another asset of Akari, PASylated-nomacopan, a long-acting type of nomacopan, is nearing the entransplant-related thrombotic microangiopathyraphic atrophy with the promise of extending the dosing interval and reducing the risk of choroidal neovascularisation.
Peak Bio will also contribute its PHP-303, a Phase II-ready programme for treating alpha-1 antitrypsin deficiency, licensed from Bayer Healthcare.
The transaction wAkarie PASylated-nomacopancond quarter of 2024, penomacopanreholder approval and other customary closing conditions. Pogeographic atrophypany plans to prioritise its programmes, establish updated timelines and expchoroidal neovascularisationn opportunities.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。